CORRECTING and REPLACING Agilent Technologies Receives Expanded FDA Approval for the Use of Dako PD-L1 …

by on September 23, 2017

SANTA CLARA, Calif.–(BUSINESS WIRE)–Third paragraph of release should read: The expanded approvals for PD-L1 IHC 22C3 pharmDx and KEYTRUDA means that these patients now have the possibility of receiving a targeted anti-PD-1 immunotherapy (instead of The expanded approvals for PD-L1 IHC 22C3 pharmDx and KEYTRUDA means that these patients now have the possibility of receiving a targeted anti-PD-L1 immunotherapy). The corrected release reads: AGILENT TECHNOLOGIES RECEIVES EXPANDED FDA APPROVAL F ……
WN.com – Health News

Comments on this entry are closed.

Previous post:

Next post: